Pharmaceutical

J&J expands dermatology portfolio with $850m Proteologix acquisition

J&J has gained access to several bispecific antibody programmes, including the Phase I-ready asset PX128 for atopic dermatitis and asthma.

May 19, 2024 - 04:00
J&J expands dermatology portfolio with $850m Proteologix acquisition
J&J has gained access to several bispecific antibody programmes, including the Phase I-ready asset PX128 for atopic dermatitis and asthma.
Read the original article

Tags:

Previous Article

Direct to consumer channels change patient-healthcare system relationship

Next Article

Sanders issues warning to Novo Nordisk amid GLP-1 drug price investigation

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Europe issues maximum antitrust fine of $475 million to Illumina over Grail deal

STAT+: Europe issues maximum antitrust fine of $475 mil...

Jul 12, 2023

STAT+: Pharmalittle: FDA probes CAR-T therapy for links to lymphoma; White House official attacks Bristol over Medicare price talks

STAT+: Pharmalittle: FDA probes CAR-T therapy for links...

Nov 29, 2023

Amylyx ventures into metabolic diseases market with $35.1m deal

Amylyx ventures into metabolic diseases market with $35...

Jun 30, 2024